Saama Collaborates with Researchers to Assess Technology Adoption in Drug Development ~ Collaboration Continues Saama’s Commitment to Academic Alliances that Advance Clinical OperationsPosted Jul 09, 2019
CAMPBELL, CA – (July 9, 2019) – Saama Technologies, Inc.(“Saama”), a leading clinical data analytics company, today announced a collaboration with researchers at theTufts Center for the Study of Drug Development(Tufts CSDD) at Tufts University School of Medicine to ascertain how biopharmaceutical companies optimize automation and information technologies, including artificial intelligence (AI) such as machine learning and neural networks, to support the research and development (R&D) of new therapeutics.
The research will examine what areas of the R&D continuum the life sciences industry sees as most easily automated, and where these innovations are being applied. In addition, the research will examine where applications of technology solutions have the most impact, assess how contract research organizations (CROs) support the adoption of these innovations, and identify areas of greatest concern and challenge.
“The clinical development process is being transformed by information technology, especially AI-powered data analytics solutions,” said Sagar Anisingaraju, Chief Strategy Officer at Saama Technologies. “Saama has embarked on this collaboration with researchers at Tufts CSDD to further inform our mission of empowering life science companies to bring better drugs to market faster, and ensure that we offer our biopharma partners optimal awareness and understanding of their technology needs as they implement their digital transformation programs.”
“We will be assessing how innovative technology solutions are being applied in drug development,” said Ken Getz, Director of Sponsored Research at Tufts CSDD. “We know that companies have been piloting select solutions, but the level of adoption of automation and IT, and its impact, has not been benchmarked.”
The work will get underway this fall and will entail both an industry roundtable, comprising participants from leading life science organizations, and a global, industry-wide survey. Saama’s collaboration with researchers at Tufts CSDD is its most recent relationship with academia to identify and advance the contributions of data analytics to life sciences. Saama previously worked with the Kellogg School of Management at Northwestern University to develop a case study about Saama’s evolution for the life sciences industry and clinical operations domain, and also partnered with Columbia University to examine the return on investment realized by data analytics solutions applied to therapeutic development.
About Saama Technologies, Inc.
Saama Technologies is the advanced clinical data and analytics company, unleashing wisdom from data to deliver better actionable business outcomes for the life sciences industry. Saama’s unified, AI-driven clinical data analytics cloud platform seamlessly integrates, curates, and animates unlimited sources of structured, unstructured, and real-world data to deliver actionable insights across all therapeutic areas. The award-winning platform gives unprecedented real-time visibility into clinical data, enabling sponsors to file New Drug Applications (NDAs) more efficiently to bring drugs to market faster and at lower costs. For more information, visit http://www.saama.com.